Core Viewpoint - Xidian Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 18.89% but a recent decline in the last five trading days by 4.10% [1] Company Overview - Xidian Pharmaceutical, established on March 21, 1990, and listed on February 23, 2022, is located in Jilin Province and specializes in the research, production, and sales of chemical pharmaceutical raw materials and formulations [1] - The company's main revenue sources are: Risperidone orally disintegrating tablets (54.15%) and Compound Ferrous Sulfate Folic Acid Tablets (45.13%), with other products contributing 0.72% [1] Financial Performance - For the period from January to September 2025, Xidian Pharmaceutical reported operating revenue of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 33.14 million yuan, down 2.70% year-on-year [1] - As of September 30, the number of shareholders decreased by 2.91% to 7,863, while the average circulating shares per person increased by 2.97% to 7,426 shares [1] Market Activity - On November 25, Xidian Pharmaceutical's stock rose by 2.05% to 30.90 yuan per share, with a trading volume of 5.4471 million yuan and a turnover rate of 0.30%, resulting in a total market capitalization of 2.364 billion yuan [1] - The stock has experienced a decline of 1.65% over the past 20 days and 5.65% over the past 60 days [1] Dividend Information - Since its A-share listing, Xidian Pharmaceutical has distributed a total of 63.34 million yuan in dividends, with 52.83 million yuan distributed over the past three years [2]
西点药业涨2.05%，成交额544.71万元